A bipartisan congressional coalition pushed back on the U.S. Drug Enforcement Administration’s assertion that cannabidiol and extracts derived from hemp are Schedule I substances.
Twenty-eight legislators including Sen. Rand Paul, R-Ky., Sen. Ron Wyden, D-Ore., and Rep. Jared Polis, D-Colo., on Thursday filed an amicus brief in support of the Hemp Industries Association’s lawsuit challenging the DEA’s new rule on “marihuana extracts.”
The Hemp Industries Association and hemp businesses last year filed a petition in the 9th U.S. Circuit Court of Appeals that claimed the DEA overstepped its bounds when enacting a rule for a new drug code for marijuana derivatives such as cannabidiol, better known as CBD. […]